Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia and overactive bladder: randomized controlled trial

INTERVENTION: tadalafil 5mg monotherapy (12 weeks) tadalafil 5mg and solifenacin 5mg combined therapy (12 weeks) CONDITION: benign prostate hyperplasia with overactive bladder PRIMARY OUTCOME: Change from baseline to end point for mean number of micturitions per 24 hours INCLUSION CRITERIA: 1. male patients aged 45 or older 2. patients with lower urinary tract symptoms (IPSS: 13 points or more) 3. patients with overactive bladder (OABSS: Q3 2 points or more and total score 3 points or more) 4. patients with prostate volume 20mL or more 5. patients with informed consent